Cambridge Antibody - Re Directorate
July 14 1997 - 2:31AM
UK Regulatory
RNS No 3319f
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
14th July 1997
Cambridge Antibody Technology Group plc
BOARD APPOINTMENTS
The board of Cambridge Antibody Technology Group plc
("CAT") is pleased to announce two executive director
appointments.
Kevin Johnson (BSc, PhD), joins the board as Research
Director. He joined CAT in June 1990 and was appointed
Vice President Research in January 1995. He is
responsible for CAT's research programmes. Prior to
joining CAT he was a fellow of the University of
Melbourne, Australia, and John Lucas Walker Senior
Student at the University of Cambridge, where he had
previously obtained his PhD. Kevin Johnson is 36.
David Glover (MA, MB, BChir, MRCP, MFPM) joins the board
as Medical Director. He joined CAT as Vice President
Medical Development in November 1994. He has held
previous posts as Medical Director of Schering Plough
(UK) and Director of Medical Affairs with Merck & Co
(UK). He has broad experience in drug development,
regulatory affairs, clinical research and medical
marketing gained during his pharmaceutical industry
career, which began in 1984. Prior to that he held a
series of hospital positions and a clinical research
fellowship at the University of Birmingham, having
qualified in medicine from the University of Cambridge in
1976. David Glover is 44.
Professor Peter Garland, Chairman of CAT, said:
"I am delighted that Kevin Johnson and David Glover
are joining CAT's board. They have both made
highly important contributions to CAT's success and
the board will benefit from their presence. I and
my colleagues look forward to working with them in
the future."
For further information, please contact:
Cambridge Antibody Technology 01763 263233
David Chiswell, Chief Executive Officer
John Aston, Finance Director
Ludgate Communications 0171 253 2252
Andrew Nicolls
END
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Oct 2023 to Oct 2024